

# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	TLING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/706,118	10/706,118 11/12/2003		Stephen C. Macevicz	55525-8045.US01	8171	
22918	7590	11/06/2006		EXAMINER		
PERKINS		_P	LU, FRANK WEI MIN			
P.O. BOX 2 MENLO PA		94026	ART UNIT	PAPER NUMBER		
				1634	1634	
				DATE MAILED: 11/06/2006		

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
	10/706,118	MACEVICZ, STEPHEN C.					
Office Action Summary	Examiner	Art Unit					
	Frank W Lu	1634					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.1: after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period of the period for reply within the set or extended period for reply will, by statute any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be tir y within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from t, cause the application to become ABANDONE	nely filed  rs will be considered timely. I the mailing date of this communication. D (35 U.S.C. § 133).					
Status							
1) Responsive to communication(s) filed on 21 S	eptember 2006.						
2a) This action is <b>FINAL</b> . 2b) ☐ This	action is non-final.						
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is							
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims							
4) ⊠ Claim(s) 28 is/are pending in the application. 4a) Of the above claim(s) is/are withdray 5) □ Claim(s) is/are allowed. 6) ⊠ Claim(s) 28 is/are rejected. 7) □ Claim(s) is/are objected to. 8) □ Claim(s) are subject to restriction and/or							
Application Papers							
9) The specification is objected to by the Examine 10) The drawing(s) filed on 12 November 2003 is/a Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Example 11.	are: a)⊠ accepted or b)□ object drawing(s) be held in abeyance. Se tion is required if the drawing(s) is ob	ne 37 CFR 1.85(a). Dijected to. See 37 CFR 1.121(d).					
Priority under 35 U.S.C. § 119							
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>							
	·						
Attachment(s)  1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413)							
2) Notice of References Cited (F10-392)  Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  Paper No(s)/Mail Date	Paper No(s)/Mail D						

Application/Control Number: 10/706,118

Art Unit: 1634

# **DETAILED ACTION**

#### CONTINUED EXAMINATION UNDER 37 CFR 1.114 AFTER FINAL REJECTION

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission of RCE and the amendment filed on September 21, 2006 have been entered. The claim pending in this application is claim 28. Rejection and/or objection not reiterated from the previous office action are hereby withdrawn in view of the response filed on September 21, 2006. Note that the amendments filed on September 21, 2006, which contain claims 23-27, do not correspond to the amendments filed on September 3, 2004 wherein claims 23-27 have been canceled.

## Claim Rejections - 35 USC § 112

2. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

## 3. New Matter

Claim 28 is rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Application/Control Number: 10/706,118

Art Unit: 1634

The limitation "a composition comprising a plurality of at least 124 different-sequence, same-length oligonucleotides" is added to the newly amended independent claim 28. First, although Table 1 of the specification describes 124 nucleotide fragments (see page 9), nowhere in Table 1 indicates that all 124 oligonucleotide fragments have the same length as recited in the claim. Second, although, based on cleavage with either 2 six cutters or 3 six cutters of restriction enzymes, the numbers of generated oligonucleotide fragments can change from 124 to 4605 (see Table 1 in page 9 of the specification), the specification fails to define or provide any disclosure to support "at least 124 different-sequence, same-length oligonucleotides" because the phrase "at least 124" includes 124 or more oligonucleotide fragments and is much broader than "124 to 4605". Third, since the words "different" and "unique" have different meanings and are not comparable, the phrase "wherein each end sequence contains the same number of basepairs; and wherein each end sequence in the plurality of oligonucleotides is unique" in claim 28 filed on February 2, 2006 does not support the limitation "at least 124 different-sequence, same-length oligonucleotides".

MPEP 2163.06 notes "If New Matter is added to the Claims, the examiner should reject the Claims under 35 U.S.C. 112, first paragraph - written description requirement. *In re Rasmussen*, 650 F.2d 1212, 211 USPQ 323 (CCPA 1981)." MPEP 2163.02 teaches that "Whenever the issue arises, the fundamental factual inquiry is whether a claim defines an invention that is clearly conveyed to those skilled in the art at the time the application was filed... If a claim is amended to include subject matter, limitations, or terminology not present in the application as filed, involving a departure from, addition to, or deletion from the disclosure of the application as filed, the examiner should conclude that the claimed subject matter is not described in that application". MPEP 2163.06 further notes "When an amendment is filed in reply to an objection or rejection based on 35 U.S.C. 112, first paragraph, a study of the entire application is often necessary to determine whether or not "new matter" is involved. *Applicant should therefore specifically point out the support for any amendments made to the disclosure*" (emphasis added).

Application/Control Number: 10/706,118

Art Unit: 1634

#### Conclusion

4. No claim is allowed.

5. Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center. The faxing of such papers must conform with the notices published in the Official Gazette, 1096 OG 30 (November 15, 1988), 1156 OG 61 (November 16, 1993), and 1157 OG 94 (December 28, 1993)(See 37 CAR § 1.6(d)). The CM Fax Center number is (571)273-8300.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Frank Lu, Ph.D., whose telephone number is (571)272-0746.

The examiner can normally be reached on Monday-Friday from 9 A.M. to 5 P.M.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla, can be reached on (571)272-0735.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

October 30, 2006

FRANK LU
PRIMARY EXAMINER

Take in